Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
61.44
-3.22 (-4.98%)
At close: Dec 5, 2025, 4:00 PM EST
62.20
+0.76 (1.24%)
After-hours: Dec 5, 2025, 7:29 PM EST
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Arrowhead Pharmaceuticals stock have an average target of 56, with a low estimate of 17 and a high estimate of 85. The average target predicts a decrease of -8.85% from the current stock price of 61.44.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Arrowhead Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 5 |
| Buy | 4 | 3 | 3 | 2 | 2 | 2 |
| Hold | 3 | 2 | 2 | 2 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 8 | 9 | 8 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $85 | Strong Buy | Maintains | $80 → $85 | +38.35% | Dec 2, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $42 → $62 | Strong Buy | Maintains | $42 → $62 | +0.91% | Dec 1, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | -2.34% | Dec 1, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $45 → $48 | Hold | Maintains | $45 → $48 | -21.87% | Nov 26, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $27 → $48 | Hold | Maintains | $27 → $48 | -21.87% | Nov 20, 2025 |
Financial Forecast
Revenue This Year
397.65M
from 829.45M
Decreased by -52.06%
Revenue Next Year
292.12M
from 397.65M
Decreased by -26.54%
EPS This Year
-3.29
from -0.01
EPS Next Year
-4.00
from -3.29
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 629.5M | 462.1M | |||
| Avg | 397.7M | 292.1M | |||
| Low | 98.0M | 111.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -24.1% | 16.2% | |||
| Avg | -52.1% | -26.5% | |||
| Low | -88.2% | -71.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.87 | -2.73 | |||
| Avg | -3.29 | -4.00 | |||
| Low | -5.34 | -6.08 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.